March 30, 2017 / 12:16 PM / 8 months ago

BRIEF-Acasti Pharma says CaPre Phase 3 on track to start in late 2017

March 30 (Reuters) - Acasti Pharma Inc:

* Acasti Pharma provides update on capre phase 3 development program

* Confirms phase 3 program is on track to start late 2017

* Acasti Pharma - FDA’s feedback supports co’s plan to conduct two studies instead of one large study, potentially shortening time to NDA submission Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below